On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five additional states, including Colorado, Minnesota, Pennsylvania, Rhode Island and Utah, as part of the joint $481 million program with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD).

This expansion doubled the number of states participating in the program. Cue expected to deliver six million tests by the spring. Cueﾒs COVID-19 Tests were being used in point-of-care settings to provide molecular confirmation to antigen tests that yield positive and suspicious negative results, eliminating the need to send results to a central lab and thereby enabling healthcare providers to respond immediately.